Now, it has decided to publish a special report on two of GSK's COPD therapies – Breo Ellipta (fluticasone furoate and vilanterol) and Trelegy Ellipta (fluticasone furoate, umeclidinium ...

Trelegy may well cannibalise sales of GSK's newer double therapy, Breo Ellipta, which is slowly gaining market share. The FDA has given Trelegy a licence for long-term, second line maintenance use ...

GSK reported core earnings of $1.27 per American ... This upside was driven by solid sales growth of the asthma inhaler Trelegy Ellipta across all regions, reflecting patient demand.

Teva Pharmaceutical Industries Ltd. ADR 26.47% $18.82B ...

Amanda Southcombe, GSK NZ General Manager, says funding for Trelegy Ellipta was recently announced, a single inhaler triple-therapy to treat the disease, which will see around 15,000 Kiwis ...

A month has gone by since the last earnings report for GSK (GSK). Shares have lost about 6.6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to ...